Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors (Q43204396)

16 November 2017

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors (English)

1 reference

16 November 2017

1 reference

Chun-Meng Wang

1

1 reference

16 November 2017

Kai Huang

2

1 reference

16 November 2017

Ye Zhou

3

1 reference

16 November 2017

Chun-Yan Du

4

1 reference

16 November 2017

Yan-Wei Ye

5

1 reference

16 November 2017

Hong Fu

6

1 reference

16 November 2017

Xiao-Yan Zhou

7

1 reference

16 November 2017

Ying-Qiang Shi

8

1 reference

16 November 2017

31 December 2009

1 reference

Journal of Cancer Research and Clinical Oncology

16 November 2017

1 reference

16 November 2017

136

1 reference

16 November 2017

7

1 reference

16 November 2017

1065-1071

1 reference

https://scigraph.springernature.com/pub.10.1007/s00432-009-0753-7

16 November 2017

0 references

cites work

Expression of COX-2, PCNA, Ki-67 and p53 in gastrointestinal stromal tumors and its relationship with histopathological parameters

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-009-0753-7

Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-009-0753-7

Prognostic value of KIT mutation in gastrointestinal stromal tumors

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00432-009-0753-7

Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

21 January 2018

1 reference

12 December 2020

Heterogeneity of kinase inhibitor resistance mechanisms in GIST

1 reference

12 December 2020

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

1 reference

12 December 2020

Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa

1 reference

12 December 2020

Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor

1 reference

12 December 2020

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

PDGFRA activating mutations in gastrointestinal stromal tumors.

1 reference

12 December 2020

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

12 December 2020

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles

1 reference

12 December 2020

Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST).

1 reference

12 December 2020

Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors

1 reference

12 December 2020

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene.

1 reference

12 December 2020

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

1 reference

12 December 2020

Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase

1 reference

12 December 2020

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

1 reference

12 December 2020

Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors

1 reference

12 December 2020

Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).

1 reference

12 December 2020

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

12 December 2020

Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors

1 reference

12 December 2020

Measuring the clinical response. What does it mean?

1 reference

12 December 2020

Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate

1 reference

12 December 2020

Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase

1 reference

12 December 2020

Familial gastrointestinal stromal tumours with germline mutation of the KIT gene

1 reference

12 December 2020

10.1007/S00432-009-0753-7

Identifiers

DOI

1 reference

release_fw33zbg7r5ar3lvkf4olgz6gmu

16 November 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fw33zbg7r5ar3lvkf4olgz6gmu

24 November 2022

mapped directly with Wikidata item

1 reference